News

Resident Wendy Liu Receives Gragoudas-Folkman Award

May 2, 2018

First-year Harvard Ophthalmology resident Wendy Liu, MD, PhD, received the 2018 Gragoudas-Folkman Award, which will provide up to $20,000 to help fund her research on mechanosensitive ion channels in primary open-angle glaucoma. She will complete the project under the guidance of her mentor Janey Wiggs, MD, PhD.

Dr. Liu earned her MD with honors from the Harvard-MIT Program in Health Sciences and Technology, and a PhD in Neurobiology from Harvard University. While at Harvard, she received the Presidential Scholarship and Martha Gray Prize for Excellence in Research....

Read more about Resident Wendy Liu Receives Gragoudas-Folkman Award

Researchers develop new class of antibiotics to fight leading superbugs

March 29, 2018

In a significant advance against drug-resistant superbugs, investigators supported by the Harvard-wide Program on Antibiotic Resistance have identified a new class of synthetic antibiotics that have been shown to be effective against Staphylococcus aureus and Enterococcus. The newly discovered antibiotics could one day help treat deadly infections caused by these superbugs.

The research group, which included Michael Gilmore, PhD, Sir William Osler Professor of...

Read more about Researchers develop new class of antibiotics to fight leading superbugs
Dr. Jason Comander

Mass. Eye and Ear performs first FDA-approved gene therapy procedure for inherited disease

March 20, 2018

Boston, Mass. — Massachusetts Eye and Ear made medical history on Tuesday by performing the first post-FDA approval gene therapy for patients with a form of inherited blindness. The occasion marks the beginning of a new era in medicine, as it is the first time any FDA-approved gene therapy has been given to a patient for any inherited disease.

The treatment, commercially identified as Luxturna, was developed by Spark Therapeutics and ...

Read more about Mass. Eye and Ear performs first FDA-approved gene therapy procedure for inherited disease

Scientists, Advocates Team Up to Launch Odylia Therapeutics to Accelerate Gene Therapy Trials for Rare Conditions Causing Blindness

March 7, 2018

New nonprofit organization will bring treatments to clinical trial for people at risk for blindness due to ultra-rare inherited retinal diseases.

Luk Vandenberghe in laboratory

Boston, Mass. — Scientists and advocates today announced the formation of ...

Read more about Scientists, Advocates Team Up to Launch Odylia Therapeutics to Accelerate Gene Therapy Trials for Rare Conditions Causing Blindness